RWD domain-containing protein 3 (RWD domain-containing sumoylation enhancer) (RSUME)
1_MAEPV 6_ QEELS 11_ VLAAI 16_ FCRPH 21_ EWEVL 26_ SRSET 31_ DGTVF 36_ RIHTK 41_ AEGFM 46_ DVDIP 51_ LELVF 56_ HLPVN 61_ YPSCL 66_ PGISI 71_ NSEQL 76_ TRAQC 81_ VTVKE 86_ NLLEQ 91_ AESLL 96_ SEPMV 101_ HELVL 106_ WIQQN 111_ LRHIL 116_ SQPET 121_ GSGSE 126_ KCTFS 131_ TSTTM 136_ DDGLW 141_ ITLLH 146_ LDHMR 151_ AKTKY 156_ VKIVE 161_ KWASD 166_ LRLTG 171_ RLMFM 176_ GKIIL 181_ ILLQG 186_ DRNNL 191_ KEYLI 196_ LQKTS 201_ KVDVD 206_ SSGKK 211_ CKEKM 216_ ISVLF 221_ ETKVQ 226_ TEHKR 231_ FLAFE 236_ VKEYS 241_ ALDEL 246_ QKEFE 251_ TAGLK 256_ KLFSE 261_FVLAL
1: Enhancer of SUMO conjugation. Via its interaction with UBE2I/UBC9, increases SUMO conjugation to proteins by promoting the binding of E1 and E2 enzymes, thioester linkage between SUMO and UBE2I/UBC9 and transfer of SUMO to specific target proteins which include HIF1A, PIAS, NFKBIA, NR3C1 and TOP1. Isoform 1 and isoform 2 positively regulate the NF-kappa-B signaling pathway by enhancing the sumoylation of NF-kappa-B inhibitor alpha (NFKBIA), promoting its stabilization which consequently leads to an increased inhibition of NF-kappa-B transcriptional activity. Isoform 1 and isoform 2 negatively regulate the hypoxia-inducible factor-1 alpha (HIF1A) signaling pathway by increasing the sumoylation of HIF1A, promoting its stabilization, transcriptional activity and the expression of its target gene VEGFA during hypoxia. Isoform 2 promotes the sumoylation and transcriptional activity of the glucocorticoid receptor NR3C1 and enhances the interaction of SUMO1 and NR3C1 with UBE2I/UBC9. Has no effect on ubiquitination